journal
MENU ▼
Read by QxMD icon Read
search

American Journal of Hematology

journal
https://read.qxmd.com/read/30785215/frontline-antibiotic-therapy-for-early-stage-helicobacter-pylori-negative-gastric-malt-lymphoma
#1
LETTER
Paolo Strati, Seung Tae Lee, Purnima Teegavarupu, Anusha Karri, Saswatha Anireddy, Fredrick B Hagemeister, Jorge Romaguera, Luis E Fayad, Maria A Rodriguez, Felipe Samaniego, Nathan Fowler, Jason Westin, Michael Wang, Hun Ju Lee, Chelsea Pinnix, Jillian R Gunther, Bouthaina Dabaja, Lei Feng, R Eric Davis, Sattva S Neelapu
No abstract text is available yet for this article.
February 20, 2019: American Journal of Hematology
https://read.qxmd.com/read/30784102/toxicities-of-cd19-car-t-cell-immunotherapy
#2
REVIEW
Alexandre V Hirayama, Cameron J Turtle
CD19-targeted chimeric antigen receptor (CAR)-modified T (CAR-T) cell immunotherapy has demonstrated impressive results in B-cell malignancies, and CAR-T cell therapies targeting other antigens are in development for other cancers. Cytokine release syndrome (CRS) and neurotoxicity can be life-threatening in a subset of patients. The severity of CRS and neurotoxicity can be impacted by the disease burden, lymphodepletion regimen, and CAR-T cell dose. Tocilizumab and corticosteroids have been used to manage these toxicities, enabling CD19 CAR-T cells to be administered without obvious compromise in efficacy...
February 19, 2019: American Journal of Hematology
https://read.qxmd.com/read/30784101/car-t-cells-for-acute-lymphoblastic-leukemia
#3
Noelle V Frey
Chimeric Antigen Receptor (CAR) modified T cells targeted to CD19 have resulted in unprecedented remission rates for adult and pediatric patients with relapsed and refractory B cell acute lymphoblastic leukemia (ALL). With regulatory approval for tisagenlecleucel and many other agents under active investigation, the use of CAR T cells for ALL continues to expand. While some remissions from anti-CD19 CAR T cells are durable without a consolidative allogeneic stem cell transplantation, CD19 positive and negative relapses remain a significant concern fueling investigations into the biology of CAR T cell persistence and the development of CARTs that target more than one antigen...
February 19, 2019: American Journal of Hematology
https://read.qxmd.com/read/30784099/rapid-and-reproducible-characterization-of-sickling-during-automated-deoxygenation-in-sickle-cell-disease-patients
#4
Minke A E Rab, Brigitte A van Oirschot, Jennifer Bos, Tesy H Merkx, Annet C W van Wesel, Osheiza Abdulmalik, Martin K Safo, A Birgitta Versluijs, Maite E Houwing, Marjon H Cnossen, Jurgen Riedl, Roger E G Schutgens, Gerard Pasterkamp, Marije Bartels, Eduard J van Beers, Richard van Wijk
In sickle cell disease (SCD), sickle hemoglobin (HbS) polymerizes upon deoxygenation, resulting in sickling of red blood cells (RBCs). These sickled RBCs have strongly reduced deformability, leading to vaso-occlusive crises and chronic hemolytic anemia. To date, there are no reliable laboratory parameters or assays capable of predicting disease severity or monitoring treatment effects. We here report on the oxygenscan: a newly developed method to measure RBC deformability (expressed as Elongation Index - EI) as a function of pO2 ...
February 19, 2019: American Journal of Hematology
https://read.qxmd.com/read/30784098/short-survival-and-frequent-transformation-in-extranodal-marginal-zone-lymphoma-with-multiple-mucosal-sites-presentation
#5
Juan Pablo Alderuccio, Wei Zhao, Amrita Desai, Jeremy Ramdial, Nicolas Gallastegui, Erik Kimble, Macarena I de la Fuente, Muhammad Husnain, Joseph D Rosenblatt, Alvaro J Alencar, Jonathan H Schatz, Craig H Moskowitz, Jennifer R Chapman, Francisco Vega, Isildinha M Reis, Izidore S Lossos
Between 11-37% of extranodal marginal zone lymphoma (EMZL) patients present with disease involvement in multiple mucosal sites (MMS). We analyzed 405 EMZL patients seen between 1995 and 2017. 265 (65.4%) presented with stage I disease, 49 of 309 (15.8%) with bone marrow involvement and 35 of 328 (10.7%) with monoclonal gammopathy (MG). 43 (10.6%) patients had MMS presentation, which was more frequently seen in patients aged >60 years (55.8%). 5(17.9%) of 28 MMS patients had MG. MMS patients commonly exhibited an IPI >2 (79...
February 19, 2019: American Journal of Hematology
https://read.qxmd.com/read/30784097/long-term-fostamatinib-treatment-of-adults-with-immune-thrombocytopenia-itp-during-the-phase-3-clinical-trial-program
#6
James B Bussel, Donald M Arnold, Michael A Boxer, Nichola Cooper, Jiri Mayer, Hany Zayed, Sandra Tong, Anne-Marie Duliege
Two randomized, double-blind, placebo-controlled studies demonstrated responses (≥50,000/μL) to fostamatinib in adults with long-standing immune thrombocytopenia (ITP). The long-term safety and efficacy of fostamatinib was evaluated in a follow-on, open-label-extension (OLE) study. Patients received double-blind fostamatinib in the randomized trials, and responders continued the same dose, 100-150mg BID, in the OLE. Non-responders received 100mg bid for 4 weeks and could escalate to 150mg bid at Week 4. Endpoints included stable response, platelet count ≥50,000/μL at 4/6 biweekly (randomized trials) or 2/3 monthly visits (OLE), and overall response, ≥1 platelet count ≥50,000/μL during Weeks 1-12...
February 19, 2019: American Journal of Hematology
https://read.qxmd.com/read/30773708/pure-erythroid-leukaemia-the-value-of-e-cadherin-in-making-the-diagnosis
#7
Imogen Caldwell, Anna Ruskova, Gordon Royle, James Liang, Barbara J Bain
No abstract text is available yet for this article.
February 17, 2019: American Journal of Hematology
https://read.qxmd.com/read/30773707/cytomegalovirus-reactivation-is-associated-with-increased-mortality-more-than-100-days-after-allogeneic-hematopoietic-stem-cell-transplantation-for-adult-t-cell-leukemia-lymphoma
#8
LETTER
Yasushi Sawayama, Hidehiro Itonaga, Takuya Fukushima, Nobuaki Nakano, Hiroshi Fujiwara, Atae Utsunomiya, Takahiro Fukuda, Toshihiro Miyamoto, Tetsuya Eto, Kaname Miyashita, Hirohisa Nakamae, Masao Ogata, Atsushi Yamanoha, Yasuhiko Miyazaki, Junya Kanda, Yoshiko Atsuta, Koji Kato
No abstract text is available yet for this article.
February 17, 2019: American Journal of Hematology
https://read.qxmd.com/read/30773682/monoclonal-gammopathy-plus-positive-amyloid-biopsy-does-not-always-equal-al-amyloidosis
#9
LETTER
M Hasib Sidiqi, Surendra Dasari, Ellen D McPhail, Francis K Buadi, Rahma Warsame, Martha Q Lacy, David Dingli, Wilson I Gonsalves, Prashant Kapoor, Taxiarchis Kourelis, Nelson Leung, Eli Muchtar, Martha Grogan, John A Lust, Shaji Kumar, Robert A Kyle, Vincent S Rajkumar, Morie Gertz, Angela Dispenzieri
No abstract text is available yet for this article.
February 17, 2019: American Journal of Hematology
https://read.qxmd.com/read/30773675/the-morbidity-and-mortality-of-end-stage-renal-disease-in-sickle-cell-disease
#10
LETTER
Maya Viner, Jifang Zhou, David Allison, Jin Han, Robert E Molokie, Shivi Jain, Michel Gowhari, Victor R Gordeuk, Gregory Calip, Santosh L Saraf
No abstract text is available yet for this article.
February 17, 2019: American Journal of Hematology
https://read.qxmd.com/read/30773670/bone-marrow-biopsy-in-low-risk-mgus-patients-reveals-a-novel-mgus-like-smoldering-multiple-myeloma-risk-group
#11
LETTER
Mark Bustoros, Efstathios Kastritis, Romanos Sklavenitis-Pistofidis, Chia-Jen Liu, Kalvis Hornburg, Nikolaos Kanellias, Geon Kim, David Liu, Maria Gavriatopoulou, Catherine R Marinac, Maria Roussou, Magdalini Migkou, Kimberly Noonan, Kaitlen Reyes, Bradley Rivotto, Carl Jannes Neuse, Dimitrios C Ziogas, Jacob Laubach, Evangelos Terpos, Kenneth C Anderson, Paul G Richardson, Irene M Ghobrial, Meletios A Dimopoulos
No abstract text is available yet for this article.
February 17, 2019: American Journal of Hematology
https://read.qxmd.com/read/30767298/outcomes-with-ibrutinib-by-line-of-therapy-and-post-ibrutinib-discontinuation-in-patients-with-cll-phase-3-analysis
#12
Susan M O'Brien, John C Byrd, Peter Hillmen, Steven Coutre, Jennifer R Brown, Paul M Barr, Jacqueline C Barrientos, Stephen Devereux, Tadeusz Robak, Nishitha M Reddy, Thomas J Kipps, Alessandra Tedeschi, Florence Cymbalista, Paolo Ghia, Stephen Chang, Joi Ninomoto, Danelle F James, Jan A Burger
The efficacy of ibrutinib has been demonstrated in patients with chronic lymphocytic leukemia (CLL), including as first-line therapy. However, outcomes after ibrutinib discontinuation have previously been limited to higher-risk populations with relapsed/refractory (R/R) disease. The objective of this study was to evaluate outcomes of ibrutinib-treated patients based on prior lines of therapy, including after ibrutinib discontinuation. Data were analyzed from two multicenter phase 3 studies of single-agent ibrutinib: RESONATE (PCYC-1112) in patients with R/R CLL and RESONATE-2 (PCYC-1115) in patients with treatment-naive (TN) CLL without del(17p)...
February 14, 2019: American Journal of Hematology
https://read.qxmd.com/read/30740766/phase-ii-study-of-carfilzomib-and-dexamethasone-kd-therapy-for-newly-diagnosed-multiple-myeloma
#13
Peter A Forsberg, Adriana C Rossi, Angelique Boyer, Linda Tegnestam, Roger N Pearse, Arthur Perry, Karen A Pekle, David Jayabalan, Scott Ely, Leora Boussi, Daniel W Sherbenou, Colt Williams, John N Allan, Morton Coleman, Ruben Niesvizky, Tomer M Mark
Carfilzomib and dexamethasone (Kd) has significant activity in relapsed and refractory multiple myeloma. Kd has not previously been evaluated in newly diagnosed multiple myeloma (NDMM). We report a single-arm phase 2 study of 72 patients with NDMM to evaluate the efficacy and tolerability of Kd induction. Carfilzomib was administered in 2 dosing cohorts with dosing of 20/45mg/m2 in the first 25 patients and 20/56mg/m2 in the subsequent 47 patients. Carfilzomib was administered on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle, dexamethasone 20mg was administered orally on days 1, 2, 8, 9, 15, 16, 22 and 23...
February 10, 2019: American Journal of Hematology
https://read.qxmd.com/read/30734369/using-an-old-test-for-new-tricks-measuring-direct-oral-anti-xa-drug-levels-by-conventional-heparin-calibrated-anti-xa-assay
#14
LETTER
Cheryl L Maier, William H Asbury, Alexander Duncan, Adele Robbins, Ann Ingle, Adam Webb, Sean R Stowell, John D Roback
No abstract text is available yet for this article.
February 7, 2019: American Journal of Hematology
https://read.qxmd.com/read/30734364/social-media-discussions-provide-new-insight-about-perceptions-of-hydroxyurea-in-the-sickle-cell-community
#15
LETTER
Aisha L Walker, Laura M Gaydos, Rosta Farzan, Laura De Castro, Charles Jonassaint
No abstract text is available yet for this article.
February 7, 2019: American Journal of Hematology
https://read.qxmd.com/read/30734356/identifying-leukemia-associated-immunophenotype-based-individualized-minimal-residual-disease-in-acute-myeloid-leukemia-and-its-prognostic-significance
#16
Jing-Ni Sui, Qiu-Sheng Chen, Yun-Xiang Zhang, Yan Sheng, Jing Wu, Jun-Min Li, Xiang-Qin Weng, Bing Chen
Based on the leukemia-associated immunophenotypes (LAIPs), minimal residual disease (MRD) related to the outcome can be detected by multiparameter flow cytometry in acute myeloid leukemia (AML) patients. Although 0.1% was commonly used as a cutoff value, measurable MRD or MRD level below 0.1% has also been associated with prognostic significance, more sensitive thresholds (<0.1%) are required for improving AML prognosis prediction. In this study, 292 adult patients diagnosed with AML (non-M3) were enrolled, 36 kinds of LAIPs were identified and the baseline expression levels in normal or regenerating bone marrows of each kind of LAIP were established, which ranged from <2...
February 7, 2019: American Journal of Hematology
https://read.qxmd.com/read/30734355/bmi-percentile-is-an-independent-predictor-of-increase-in-lung-function-in-children-with-sickle-cell-anemia
#17
LETTER
Jodi-Anne T Stewart, Shaina M Willen, Robyn Cohen, Mark Rodeghier, Fenella Kirkham, Susan S Redline, Carol Rosen, Jane Kirkby, Michael R DeBaun
No abstract text is available yet for this article.
February 7, 2019: American Journal of Hematology
https://read.qxmd.com/read/30734351/clinicopathologic-features-management-and-outcomes-of-plasmablastic-lymphoma-a-ten-year-experience
#18
LETTER
Nivedita Arora, Corbin Eule, Arjun Gupta, Hsiao C Li, Navid Sadeghi
No abstract text is available yet for this article.
February 7, 2019: American Journal of Hematology
https://read.qxmd.com/read/30734350/clinical-and-economic-burden-of-regularly-transfused-adult-patients-with-%C3%AE-thalassemia-in-the-united-states-a-retrospective-cohort-study-using-payer-claims
#19
LETTER
Mia Weiss, Monika Parisi Jun, Sujit Sheth
No abstract text is available yet for this article.
February 7, 2019: American Journal of Hematology
https://read.qxmd.com/read/30730071/car-t-cell-immunotherapy-for-multiple-myeloma-a-review-of-current-data-and-potential-clinical-applications
#20
Sandra P Susanibar Adaniya, Adam D Cohen, Alfred L Garfall
Multiple myeloma (MM) is a malignant plasma cell disorder that remains incurable for most patients despite significant improvements achieved with modern therapy. Tumor evasion is a key process in the pathogenesis of MM and a compromised immune system is associated with more aggressive forms of the disease. In contrast, the emergence of myeloma-specific immune responses after both autologous and allogeneic stem cell transplantation is associated with better prognosis. Adoptive T cell therapies may improve specific anti-myeloma immunity resulting in long-lasting remissions...
February 7, 2019: American Journal of Hematology
journal
journal
26814
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"